UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study

Annals of oncology, 2015-07, Vol.26 (7), p.1427-1433

2015

Volltextzugriff (PDF)

The Mass of Geniohyoid Muscle Is Associated with Maximum Tongue Pressure and Tongue Area in Patients with Sarcopenic Dysphagia

The Journal of nutrition, health & aging, 2021-03, Vol.25 (3), p.356-360

2021

Volltextzugriff (PDF)

Prevalence of Hoarseness and Its Association with Severity of Dysphagia in Patients with Sarcopenic Dysphagia

The Journal of nutrition, health & aging, 2022-03, Vol.26 (3), p.266-271

2022

Volltextzugriff (PDF)

Association between Inflammation and Functional Outcome in Patients with Sarcopenic Dysphagia

The Journal of nutrition, health & aging, 2022-04, Vol.26 (4), p.400-406

2022

Volltextzugriff (PDF)

Clinical efficacy of Daikenchuto for gastrointestinal dysfunction following colon surgery: a randomized, double-blind, multicenter, placebo-controlled study (JFMC39-0902)

Japanese journal of clinical oncology, 2015-07, Vol.45 (7), p.650-656

2015

Volltextzugriff (PDF)

Positive effects of roflumilast on behavior, neuroinflammation, and white matter injury in mice with global cerebral ischemia

Behavioural pharmacology, 2021-09, Vol.32 (6), p.459-471

2021

Volltextzugriff (PDF)

Activation of p38 mitogen-activated protein kinase mediates thyroid hormone-stimulated osteocalcin synthesis in osteoblasts

Molecular and cellular endocrinology, 2004-02, Vol.214 (1), p.189-195

2004

Volltextzugriff (PDF)

P-100 A phase II study of first-line chemotherapy initiating FOLFIRI+cetuximab and switching to FOLFIRI+bevacizumab according to early tumor shrinkage at 8 weeks in RAS wild-type metastatic colorectal cancer: HYBRID trial

Annals of oncology, 2021-07, Vol.32, p.S132

2021

Volltextzugriff (PDF)

Expression of vanilloid VR1 receptor in PC12 cells

Neurochemistry international, 2004-12, Vol.45 (7), p.1005-1010

2004

Volltextzugriff (PDF)

Polo‐like kinase 1 (PLK1) is overexpressed in primary colorectal cancers

Cancer science, 2003-02, Vol.94 (2), p.148-152

2003

Volltextzugriff (PDF)

Cloning, sequencing and heterologous expression of the medermycin biosynthetic gene cluster of Streptomyces sp. AM-7161: towards comparative analysis of the benzoisochromanequinone gene clusters

Microbiology (Society for General Microbiology), 2003-07, Vol.149 (Pt 7), p.1633-1645

2003

Volltextzugriff (PDF)

Phase III trial of 24 weeks vs. 48 weeks capecitabine adjuvant chemotherapy for patients with stage III colon cancer: Final results of JFMC37-0801

Annals of oncology, 2016-10, Vol.27, p.vi155-vi155

2016

Volltextzugriff (PDF)

Detection of peritoneal micrometastases by reverse transcriptase-polymerase chain reaction targeting carcinoembryonic antigen and cytokeratin 20 in colon cancer patients

Journal of experimental & clinical cancer research, 2002-12, Vol.21 (4), p.555-562

2002

Volltextzugriff (PDF)

A Phase III Study of Eagle Comparing Two Doses of Bevacizumab Combined with Folfiri in the Second-Line Setting After First-Line Treatment with Bevacizumab Plus Oxaliplatin-Based Therapy : Kras Subgroup Findings

Annals of oncology, 2014-09, Vol.25, p.iv179

2014

Volltextzugriff (PDF)

525PA PHASE III STUDY OF EAGLE COMPARING TWO DOSES OF BEVACIZUMAB COMBINED WITH FOLFIRI IN THE SECOND-LINE SETTING AFTER FIRST-LINE TREATMENT WITH BEVACIZUMAB PLUS OXALIPLATIN-BASED THERAPY : KRAS SUBGROUP FINDINGS

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv179-iv179

2014

Volltextzugriff (PDF)

460PPHASE I CLINICAL TRIAL OF DS-7423, AN ORAL PI3K/MTOR DUAL INHIBITOR, IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv153-iv153

2014

Volltextzugriff (PDF)

Phase I Clinical Trial of Ds-7423, an Oral Pi3K/Mtor Dual Inhibitor, in Japanese Patients with Advanced Solid Tumors

Annals of oncology, 2014-09, Vol.25, p.iv153

2014

Volltextzugriff (PDF)

Preparation of Carbided WO3/FSM-16 and Al-FSM-16 and Its Catalytic Activity

Studies in Surface Science and Catalysis, 2003, Vol.146, p.733-736

2003

Volltextzugriff (PDF)

Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma

Cancer, 1994-08, Vol.74 (3), p.817-825

1994

Volltextzugriff (PDF)

Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma

Cancer, 1994-08, Vol.74 (3), p.817-825

1994

Volltextzugriff (PDF)

An emulator for peer-to-peer distributed hash tables

Computer communications, 2009-08, Vol.32 (13), p.1559-1567

2009

Volltextzugriff (PDF)

Neuroprotective effects of goshajinkigan (TJ-107) in colorectal cancer patients receiving oxaliplatin-based chemotherapy: A double-blind, placebo-controlled, randomized phase II trial from the GONE Study Group

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e14007-e14007

2011

Volltextzugriff (PDF)

Immunochemotherapy for cancer patients of the stomach--cancer therapy keeping with good host-immunocompetency

Nihon rinshō, 2001-04, Vol.59 Suppl 4, p.420

2001

Volltextzugriff (PDF)

Significance of detection of micrometastases in regional lymph nodes in cancer patients using RT-PCR

Nihon Geka Gakkai zasshi, 2001-06, Vol.102 (6), p.449

2001

Volltextzugriff (PDF)

Implantation treatment method of slow release anticancer doxorubicin containing hydroxyapatite (DOX-HAP) complex. A basic study of a new treatment for hepatic cancer

British journal of cancer, 1993-04, Vol.67 (4), p.668-673

1993

Volltextzugriff (PDF)

1 – 25 von 799

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(616)
Mit Volltextzugriff
(622)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study

The Mass of Geniohyoid Muscle Is Associated with Maximum Tongue Pressure and Tongue Area in Patients with Sarcopenic Dysphagia

Prevalence of Hoarseness and Its Association with Severity of Dysphagia in Patients with Sarcopenic Dysphagia

Association between Inflammation and Functional Outcome in Patients with Sarcopenic Dysphagia

Clinical efficacy of Daikenchuto for gastrointestinal dysfunction following colon surgery: a randomized, double-blind, multicenter, placebo-controlled study (JFMC39-0902)

Positive effects of roflumilast on behavior, neuroinflammation, and white matter injury in mice with global cerebral ischemia

Activation of p38 mitogen-activated protein kinase mediates thyroid hormone-stimulated osteocalcin synthesis in osteoblasts

P-100 A phase II study of first-line chemotherapy initiating FOLFIRI+cetuximab and switching to FOLFIRI+bevacizumab according to early tumor shrinkage at 8 weeks in RAS wild-type metastatic colorectal cancer: HYBRID trial

Expression of vanilloid VR1 receptor in PC12 cells

Polo‐like kinase 1 (PLK1) is overexpressed in primary colorectal cancers

Cloning, sequencing and heterologous expression of the medermycin biosynthetic gene cluster of Streptomyces sp. AM-7161: towards comparative analysis of the benzoisochromanequinone gene clusters

Phase III trial of 24 weeks vs. 48 weeks capecitabine adjuvant chemotherapy for patients with stage III colon cancer: Final results of JFMC37-0801

Detection of peritoneal micrometastases by reverse transcriptase-polymerase chain reaction targeting carcinoembryonic antigen and cytokeratin 20 in colon cancer patients

A Phase III Study of Eagle Comparing Two Doses of Bevacizumab Combined with Folfiri in the Second-Line Setting After First-Line Treatment with Bevacizumab Plus Oxaliplatin-Based Therapy : Kras Subgroup Findings

525PA PHASE III STUDY OF EAGLE COMPARING TWO DOSES OF BEVACIZUMAB COMBINED WITH FOLFIRI IN THE SECOND-LINE SETTING AFTER FIRST-LINE TREATMENT WITH BEVACIZUMAB PLUS OXALIPLATIN-BASED THERAPY : KRAS SUBGROUP FINDINGS

460PPHASE I CLINICAL TRIAL OF DS-7423, AN ORAL PI3K/MTOR DUAL INHIBITOR, IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS

Phase I Clinical Trial of Ds-7423, an Oral Pi3K/Mtor Dual Inhibitor, in Japanese Patients with Advanced Solid Tumors

Preparation of Carbided WO3/FSM-16 and Al-FSM-16 and Its Catalytic Activity

Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma

Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma

An emulator for peer-to-peer distributed hash tables

Neuroprotective effects of goshajinkigan (TJ-107) in colorectal cancer patients receiving oxaliplatin-based chemotherapy: A double-blind, placebo-controlled, randomized phase II trial from the GONE Study Group

Immunochemotherapy for cancer patients of the stomach--cancer therapy keeping with good host-immunocompetency

Significance of detection of micrometastases in regional lymph nodes in cancer patients using RT-PCR

Implantation treatment method of slow release anticancer doxorubicin containing hydroxyapatite (DOX-HAP) complex. A basic study of a new treatment for hepatic cancer

Suchergebnisse filtern